Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -0.82 Increased by +8.89% | -0.84 Increased by +2.38% |
| Aug 7, 24 | -0.58 Increased by +13.43% | -0.68 Increased by +14.71% |
| May 2, 24 | -0.62 Increased by +11.43% | -0.73 Increased by +15.07% |
| Feb 22, 24 | -0.25 Increased by +58.33% | -0.40 Increased by +37.50% |
| Nov 2, 23 | -0.90 Decreased by -13.92% | -0.64 Decreased by -40.63% |
| Aug 3, 23 | -0.67 Increased by +14.10% | -0.71 Increased by +5.63% |
| May 4, 23 | -0.70 Increased by +1.41% | -0.68 Decreased by -2.94% |
| Feb 23, 23 | -0.60 Increased by +9.09% | -0.63 Increased by +4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 3.74 M Decreased by -20.88% | -62.49 M Decreased by -18.20% | Decreased by -1.67 K% Decreased by -49.38% |
| Jun 30, 24 | 25.65 M Increased by +55.33% | -42.06 M Decreased by -8.41% | Decreased by -163.98% Increased by +30.21% |
| Mar 31, 24 | 10.29 M Increased by +8.67% | -48.56 M Decreased by -32.72% | Decreased by -472.02% Decreased by -22.13% |
| Dec 31, 23 | 47.88 M Increased by +196.70% | -14.37 M Increased by +57.80% | Decreased by -30.01% Increased by +85.78% |
| Sep 30, 23 | 4.73 M Decreased by -50.50% | -52.87 M Decreased by -28.56% | Decreased by -1.12 K% Decreased by -159.71% |
| Jun 30, 23 | 16.51 M Increased by +43.42% | -38.80 M Increased by +2.28% | Decreased by -234.96% Increased by +31.86% |
| Mar 31, 23 | 9.47 M Decreased by -1.62% | -36.59 M Decreased by -0.41% | Decreased by -386.49% Decreased by -2.07% |
| Dec 31, 22 | 16.14 M Increased by +5.66% | -34.05 M Decreased by -0.43% | Decreased by -210.96% Increased by +4.95% |